SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.33-0.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: david james who wrote (1100)5/17/2000 11:00:00 PM
From: Mike McFarland  Read Replies (3) of 52153
 
David, there is a thread for that, please do come by--
Subject 27352

While I'm here, many many others at ASCO besides just
the few names dropped in the article--plus research
centers and such--you can drown in abstracts for these
sorts of meetings. But there are certainly a few
techniques that seem to be getting extra attention
lately. Dentritic cells fused with antigens--lots of
work with dentritic cells and cancer therapies.

Something I would like to ask the biogurus:
Suppose you had a phase I trial with just a
very few patients. And say a third had their
cancer stabilized by the experiment. That seems
like a pretty good result to me--assuming that
the folks who get into these experimental cancer
trials are terribly ill, last ditch effort sort
of work. Any pointers--wait for phase II I suppose?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News